17 results
8-K
EX-99.2
THRX
Theseus Pharmaceuticals Inc
25 May 23
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
5:04pm
contain black box warnings on their USPIs; in clinical trials, bosutinib and dasatinib patients discontinued at a rate of ~20% due to adverse reactions
PRE 14A
cge68fzi
14 Apr 23
Preliminary proxy
9:00am
DEF 14A
84w4gqcya51
25 Apr 22
Definitive proxy
4:30pm
10-K
j1bzkwaysu5toox33
10 Mar 22
Annual report
7:23am
10-Q
ai7 tha6tyml6e9fr
15 Nov 21
Quarterly report
7:36am
424B4
b5xx3e7smuim3xjgx n4
7 Oct 21
Prospectus supplement with pricing info
5:03pm
S-1/A
z1tobw 7x2n
30 Sep 21
IPO registration (amended)
6:33am
S-1
7nygf 0p1
15 Sep 21
IPO registration
4:04pm
DRS/A
0ek4onk p9jw
23 Aug 21
Draft registration statement (amended)
12:00am
DRS
bjqm00q9pac
20 Jul 21
Draft registration statement
12:00am
- Prev
- 1
- Next